Amber Salzman, Epic Bio CEO

Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Kite, the Gilead sub­sidiary spe­cial­iz­ing in CAR-T, is try­ing out epi­ge­net­ic edit­ing as it seeks new ways to cre­ate next-gen­er­a­tion cell ther­a­pies that are more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.